Alnylam Pharmaceuticals Inc

ALNY · Health Technology · Biotechnology · US

2,500 employees · alnylam.com

About

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA-based therapeutics for the treatment of severe genetic and other diseases. The company was founded in 2002 by John Maraganore and Phillip Sharp and is headquartered in Cambridge, Massachusetts.

Annual results

Reported figures, USD · revenue up 65.2% in 2025

YearRevenueNet incomeNet marginFree cash flow
20253.7B313M8.4%—
20242.2B-278M-12.4%—
20231.8B-440M-24.1%—
20221.0B-1.1B-109.1%—
2021844M-852M-100.9%—

ALNY in MarketPulse

The live chart with RSI and moving averages, the price, news, signals and price alerts for Alnylam Pharmaceuticals Inc are inside MarketPulse — currently in private beta.

Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.

Alnylam Pharmaceuticals Inc (ALNY) — company profile and financials · MarketPulse